Avidity Biosciences, Inc.

NasdaqGM RNA

Avidity Biosciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -188.51 M

Avidity Biosciences, Inc. Free Cash Flow is USD -188.51 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -5.33% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Avidity Biosciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -178.97 M, a -40.95% change year over year.
Avidity Biosciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -126.97 M, a -51.27% change year over year.
Avidity Biosciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -83.94 M, a -179.72% change year over year.
Avidity Biosciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -30.01 M.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqGM: RNA

Avidity Biosciences, Inc.

CEO	Ms. Sarah Boyce
IPO Date	June 12, 2020
Location	United States
Headquarters	10578 Science Center Drive
Employees	253
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Key trends

Past 5 years